These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 31733275)

  • 1. Diagnostic Properties of Total and Free Prostate-Specific Antigen to Predict Overall and Clinically Significant Prostate Cancer Among Men With Low Testosterone and Prior Negative Biopsy.
    Schwarzman LS; Pagani RL; Ohlander SJ; Mima M; Abern MR; Andriole GL; Freedland SJ; Moreira DM
    Urology; 2020 Mar; 137():97-101. PubMed ID: 31733275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
    Muller RL; Gerber L; Moreira DM; Andriole G; Castro-Santamaria R; Freedland SJ
    Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
    Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
    BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial.
    Fowke JH; Howard L; Andriole GL; Freedland SJ
    Eur Urol; 2014 Dec; 66(6):1133-8. PubMed ID: 24568894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
    Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
    Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
    Andriole GL; Bostwick D; Brawley OW; Gomella L; Marberger M; Montorsi F; Pettaway C; Tammela TL; Teloken C; Tindall D; Freedland SJ; Somerville MC; Wilson TH; Fowler I; Castro R; Rittmaster RS;
    J Urol; 2011 Jan; 185(1):126-31. PubMed ID: 21074214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher sex hormone-binding globulin and lower bioavailable testosterone are related to prostate cancer detection on prostate biopsy.
    García-Cruz E; Carrión Puig A; García-Larrosa A; Sallent A; Castañeda-Argáiz R; Piqueras M; Ribal MJ; Leibar-Tamayo A; Romero-Otero J; Alcaraz A
    Scand J Urol; 2013 Aug; 47(4):282-9. PubMed ID: 23181478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk.
    Gurbuz C; Canat L; Atis G; Guner B; Caskurlu T
    Kaohsiung J Med Sci; 2012 Dec; 28(12):649-53. PubMed ID: 23217356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional value of the ratio of serum total testosterone to total prostate-specific antigen in the diagnosis of prostate cancer in a Chinese population.
    Xu L; Hu X; Zhu Y; Lu J; Xu Y; Wang G; Guo J
    Andrologia; 2018 Mar; 50(2):. PubMed ID: 28752596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen increase during dutasteride to indicate the need for prostate biopsy: influence of prostatic inflammation.
    Sciarra A; Maggi M; Fasulo A; Salciccia S; Gentile V; Cattarino S; Gentilucci A
    Urologia; 2017 Aug; 84(3):158-164. PubMed ID: 28430341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
    García-Cruz E; Piqueras M; Huguet J; Peri L; Izquierdo L; Musquera M; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
    BJU Int; 2012 Dec; 110(11 Pt B):E541-6. PubMed ID: 22584031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone.
    Liu J; Dong B; Qu W; Wang J; Xu Y; Yu S; Zhang X
    Sci Rep; 2020 Mar; 10(1):5157. PubMed ID: 32198373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
    Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster RS; Andriole GL; Groskopf J
    Urology; 2011 Aug; 78(2):380-5. PubMed ID: 21820580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of MRI targeted prostate biopsy for detecting clinically significant prostate cancer in men with low prostate-specific antigen levels.
    Bang S; Yu J; Chung JH; Song W; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Lee HM; Jeon SS
    Sci Rep; 2021 Nov; 11(1):21951. PubMed ID: 34753938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate Health Index (PHI) improves prostate cancer detection at initial biopsy in Taiwanese men with PSA 4-10 ng/mL.
    Hsieh PF; Chang CH; Yang CR; Huang CP; Chen WC; Yeh CC; Chou EC; Chen KL; Lien CS; Chen GH; Hsiao PJ; Chang YH; Wu HC
    Kaohsiung J Med Sci; 2018 Aug; 34(8):461-466. PubMed ID: 30041764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study.
    Sourbeer KN; Howard LE; Andriole GL; Moreira DM; Castro-Santamaria R; Freedland SJ; Vidal AC
    BJU Int; 2015 May; 115(5):736-43. PubMed ID: 24931061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CLINICOPATHOLOGICAL STUDY OF PROSTATE BIOPSY IN PATIENTS RECEIVING DUTASTERIDE FOR BENIGN PROSTATIC HYPERPLASIA].
    Endo T; Kamiya N; Yano M; Oka R; Lee FC; Utsumi T; Kamijima S; Nishimi D; Takanami M; Hiruta N; Suzuki H
    Nihon Hinyokika Gakkai Zasshi; 2015 Jul; 106(3):156-62. PubMed ID: 26419072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer.
    Nordström T; Akre O; Aly M; Grönberg H; Eklund M
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):57-63. PubMed ID: 29259293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early dutasteride monotherapy in men with detectable serum prostate-specific antigen levels following radical prostatectomy: A prospective trial.
    Shin YS; Lee JW; Kim MK; Jeong YB; Park SC
    Investig Clin Urol; 2017 Mar; 58(2):98-102. PubMed ID: 28261678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.